Details of Disease

General Information of Disease (ID: DISXXX35)

• Disease Name: Hepatitis
• Synonyms: Hepatitides; chronic persistent hepatitis; chronic hepatitis; animal hepatitis; acute/subac. necrosis of liver; acute hepatitis; acute and subacute liver necrosis; liver inflammation; inflammation of liver; hepatitis; Hepatitis
• Disease Class: DB97: Inflammatory liver disease
• Definition: An active inflammatory process affecting the liver for more than six months. Causes include viral infections, autoimmune disorders, drugs, and metabolic disorders.
• Disease Hierarchy:
  DIS2OMMF: Liver disease
  DIS184KT: Skin inflammation
  DISH7H5I: Human disease
  DISXXX35: Hepatitis
• ICD Code:
  ICD-11: ICD-11: DB97.Z
  Expand ICD-11: 'DB97.Z
• Disease Identifiers:
  MONDO ID: MONDO_0002251
  MESH ID: D006505
  UMLS CUI: C0019158
  MedGen ID: 5515
  HPO ID: HP:0012115
  SNOMED CT ID: 128241005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 84 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
1,2,4-oxadiazole derivative 1	DMESOA8	Patented	Small molecule immunotherapy	[1]
1,2,4-oxadiazole derivative 2	DMA42SB	Patented	Small molecule immunotherapy	[1]
1,2,4-oxadiazole derivative 4	DMT6EDP	Patented	Small molecule immunotherapy	[1]
1,2,4-oxadiazole derivative 5	DM683R7	Patented	Small molecule immunotherapy	[1]
1,2,4-oxadiazole derivative 6	DMFYKBJ	Patented	Small molecule immunotherapy	[1]
1,2,4-oxadiazole derivative 7	DMBT4RJ	Patented	Small molecule immunotherapy	[1]
1,3,4-oxadiazole derivative 1	DMJMCNP	Patented	Small molecule immunotherapy	[1]
1,3,4-oxadiazole derivative 2	DMH26EO	Patented	Small molecule immunotherapy	[1]
1,3,4-oxadiazole derivative 3	DMSR0X6	Patented	Small molecule immunotherapy	[1]
1,3,4-oxadiazole derivative 4	DM4GR2C	Patented	Small molecule immunotherapy	[1]
1,3,4-oxadiazole derivative 5	DMI5VZN	Patented	Small molecule immunotherapy	[1]
1,3,4-oxadiazole derivative 6	DMIEZ6L	Patented	Small molecule immunotherapy	[1]
1,3,4-thiadiazole derivative 1	DMAB8QF	Patented	Small molecule immunotherapy	[1]
1,3,4-thiadiazole derivative 2	DMXIG07	Patented	Small molecule immunotherapy	[1]
1,3-dihydroxy phenyl derivative 1	DMUS7O3	Patented	Small molecule immunotherapy	[1]
1,3-dihydroxy phenyl derivative 2	DM63NX5	Patented	Small molecule immunotherapy	[1]
3-substituted-1,2,4-oxadiazole derivative 1	DMWCT04	Patented	Small molecule immunotherapy	[1]
3-substituted-1,2,4-oxadiazole derivative 2	DMB3806	Patented	Small molecule immunotherapy	[1]
Aromatic acetylene derivative 1	DMGR6X1	Patented	Small molecule immunotherapy	[1]
Aromatic ethylene derivative 1	DMSRKON	Patented	Small molecule immunotherapy	[1]
Benzyl phenyl ether derivative 1	DM6PTOX	Patented	Small molecule immunotherapy	[1]
Benzyl phenyl ether derivative 2	DMMS4EI	Patented	Small molecule immunotherapy	[1]
Biaryl compound 1	DMHEAJQ	Patented	Small molecule immunotherapy	[1]
Biaryl compound 2	DMS8VYE	Patented	Small molecule immunotherapy	[1]
Bromo benzyl ether derivative 1	DMMXQJU	Patented	Small molecule immunotherapy	[1]
Bromo benzyl ether derivative 2	DMVBAUC	Patented	Small molecule immunotherapy	[1]
Cyclic compound 1	DMSVMUT	Patented	Small molecule immunotherapy	[1]
Cyclic compound 2	DMGRBAJ	Patented	Small molecule immunotherapy	[1]
Cyclic compound 3	DMVOEN7	Patented	Small molecule immunotherapy	[1]
Cyclic peptidomimetic derivative 1	DMV2UQ5	Patented	Small molecule immunotherapy	[1]
Cyclic peptidomimetic derivative 2	DMWH3FP	Patented	Small molecule immunotherapy	[1]
Cyclic peptidomimetic derivative 3	DMI7KG4	Patented	Small molecule immunotherapy	[1]
Macrocycle derivative 1	DMN7I9C	Patented	Small molecule immunotherapy	[1]
Macrocycle derivative 2	DM5OEQZ	Patented	Small molecule immunotherapy	[1]
Macrocycle derivative 3	DMYGFTI	Patented	Small molecule immunotherapy	[1]
Macrocycle derivative 4	DMOQBN4	Patented	Small molecule immunotherapy	[1]
Macrocycle derivative 5	DMK3UJY	Patented	Small molecule immunotherapy	[1]
Macrocycle derivative 6	DMQ84KW	Patented	Small molecule immunotherapy	[1]
Macrocycle derivative 7	DMP2JF0	Patented	Small molecule immunotherapy	[1]
Macrocycle derivative 8	DMOMTBE	Patented	Small molecule immunotherapy	[1]
Macrocycle derivative 9	DMARU0E	Patented	Small molecule immunotherapy	[1]
Macrocyclic peptide analog 1	DMS65IT	Patented	Small molecule immunotherapy	[1]
Macrocyclic peptide analog 2	DMOGLBZ	Patented	Small molecule immunotherapy	[1]
Macrocyclic peptide analog 3	DMV172W	Patented	Small molecule immunotherapy	[1]
N-phenyl-pyridine-2-carboxamide derivative 1	DMMDYAV	Patented	Small molecule immunotherapy	[1]
N-phenyl-pyridine-2-carboxamide derivative 2	DM6OG2Y	Patented	Small molecule immunotherapy	[1]
Peptide analog 1	DMF3LIX	Patented	Peptide	[1]
Peptide analog 2	DMYFUM6	Patented	Peptide	[1]
Peptide analog 3	DMYMJV3	Patented	Peptide	[1]
Peptide analog 4	DM5KEVG	Patented	Peptide	[1]
Peptide analog 5	DM8B13I	Patented	Peptide	[1]
Peptide analog 6	DM68M0G	Patented	Peptide	[1]
Phenylate derivative 1	DMEO9QB	Patented	Small molecule immunotherapy	[1]
Phenylate derivative 2	DMG0ZSY	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example1	DMY37VQ	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example11	DMD65GU	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example12	DMN2K10	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example13	DM4CN9K	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example14	DMAUFS7	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example15	DMYHQ0S	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example16	DM6EKIV	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example2	DM9HMB4	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example3	DMDCN43	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example4	DMRKLTE	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example41	DMQPIK4	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example42	DM95FIN	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example43	DMJSH0F	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example44	DM8KAIY	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example45	DMC075A	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example46	DMYFSAD	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example47	DM1TCBQ	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example48	DMH57FG	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example49	DM4D1WK	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example50	DMV15GM	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example51	DM08CBJ	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example52	DMJ1C0A	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example53	DM39FDV	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example54	DM9DL1E	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example57	DMZXC0D	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example58	DM3AY9K	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example59	DM6XWL9	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example60	DMUZ85A	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example7	DMS42KH	Patented	Small molecule immunotherapy	[1]
PMID30107136-Compound-Example8	DMBIK28	Patented	Small molecule immunotherapy	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 86 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
APOBEC3G	TTP96KH	Limited	Biomarker	[2]
APOC3	TTXOZQ1	Limited	Biomarker	[3]
CMKLR1	TT4UGZL	Limited	Altered Expression	[4]
CPT1B	TTDL0NY	Limited	Biomarker	[5]
DEPTOR	TTLYP6D	Limited	Altered Expression	[6]
FFAR4	TT08JVB	Limited	Biomarker	[7]
GRB2	TTEYRJ9	Limited	Biomarker	[8]
IL17A	TTG0MT6	Limited	Biomarker	[9]
IL22	TTLDX4N	Limited	Biomarker	[9]
P2RX1	TTJW7B3	Limited	Biomarker	[10]
P2RX3	TT2THBD	Limited	Biomarker	[10]
SORT1	TTRX9AV	Limited	Biomarker	[11]
TDP2	TTYF26D	Limited	Genetic Variation	[12]
CASP1	TTCQIBE	moderate	Biomarker	[13]
CAT	TTPS279	moderate	Biomarker	[14]
HNRNPA2B1	TT8UPW6	moderate	Altered Expression	[15]
MANF	TT56RYE	moderate	Biomarker	[16]
PARP1	TTVDSZ0	moderate	Biomarker	[17]
SLC17A5	TTFSUIA	moderate	Biomarker	[18]
STAT1	TTN7R6K	moderate	Altered Expression	[19]
TXNIP	TTTLDZK	moderate	Biomarker	[20]
ABCC2	TTFLHJV	Strong	Biomarker	[21]
AFP	TTCFEA1	Strong	Biomarker	[22]
ALB	TTFNGC9	Strong	Genetic Variation	[23]
APOA2	TTGQA9W	Strong	Biomarker	[24]
ATP7B	TTOPO51	Strong	Genetic Variation	[25]
BIRC7	TTHZ8TA	Strong	Altered Expression	[26]
CD58	TT5KSBY	Strong	Altered Expression	[27]
CXCL10	TTQOVYA	Strong	Altered Expression	[28]
CXCL11	TTWG0RE	Strong	Altered Expression	[28]
CXCL2	TTZF0K2	Strong	Altered Expression	[29]
CYP2E1	TTWVHQ5	Strong	Biomarker	[30]
EHMT1	TTOFXD7	Strong	Biomarker	[31]
ENPP2	TTSCIM2	Strong	Biomarker	[32]
ESRRB	TTKF0XS	Strong	Genetic Variation	[29]
F10	TTCIHJA	Strong	Biomarker	[33]
F2R	TTL935N	Strong	Biomarker	[34]
FASLG	TTO7014	Strong	Biomarker	[35]
FCGR2B	TT5RWKQ	Strong	Altered Expression	[36]
FGL2	TTYBS89	Strong	Altered Expression	[37]
FOXP3	TT1X3QF	Strong	Biomarker	[38]
GABRG3	TTEX6LM	Strong	Genetic Variation	[39]
GGT1	TTZVT7O	Strong	Biomarker	[18]
GLP1R	TTVIMDE	Strong	Biomarker	[31]
GPR39	TTTPCNU	Strong	Altered Expression	[40]
GSR	TTEP6RV	Strong	Biomarker	[14]
GZMB	TTKEPHX	Strong	Biomarker	[35]
HKDC1	TTVUI8G	Strong	Altered Expression	[41]
HMOX1	TTI6V2A	Strong	Altered Expression	[42]
IFNL1	TTM624L	Strong	Altered Expression	[43]
IL17D	TTC5LTG	Strong	Biomarker	[44]
IL33	TT5MD4P	Strong	Biomarker	[45]
IL5	TTPREZD	Strong	Biomarker	[45]
INS	TTZOPHG	Strong	Biomarker	[46]
KEAP1	TT3Z6Y9	Strong	Biomarker	[47]
KIR2DS1	TTVWAGF	Strong	Biomarker	[48]
KIR3DL2	TTQH3N0	Strong	Biomarker	[48]
KLRK1	TTLRN4A	Strong	Biomarker	[49]
LTBR	TTFO0PM	Strong	Biomarker	[50]
MYD88	TTB6Q2O	Strong	Altered Expression	[51]
NR0B2	TT25A9Q	Strong	Biomarker	[29]
OTC	TT5KIO9	Strong	Biomarker	[52]
PARP2	TTQ4V96	Strong	Altered Expression	[17]
PCSK1	TTED9LZ	Strong	Altered Expression	[53]
PLP2	TTK5OG6	Strong	Biomarker	[54]
PNPLA3	TTEUAEH	Strong	Genetic Variation	[55]
PTGES	TTYLQ8V	Strong	Genetic Variation	[56]
RHD	TTLCKI8	Strong	Genetic Variation	[57]
RNASEL	TT7V0K4	Strong	Altered Expression	[58]
RNF34	TTEWDK1	Strong	Biomarker	[59]
SERPINA1	TTA7UJC	Strong	Biomarker	[60]
SERPINB3	TT6QLPX	Strong	Altered Expression	[61]
SMN1	TT8QL6X	Strong	Biomarker	[62]
SOCS3	TTI0ME6	Strong	Biomarker	[63]
SPARC	TTBQFM7	Strong	Biomarker	[64]
TBX21	TTNF9PH	Strong	Genetic Variation	[65]
TDO2	TTXNCBV	Strong	Biomarker	[66]
TEC	TT1ZV49	Strong	Genetic Variation	[67]
TF	TT8WXAV	Strong	Biomarker	[34]
TIPARP	TT2FRAN	Strong	Altered Expression	[68]
TLR6	TTWRI8V	Strong	Biomarker	[69]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[70]
TYRO3	TTIEMFN	Strong	Altered Expression	[71]
UGT1A1	TT34ZAF	Strong	Genetic Variation	[72]
VIPR1	TTCL30I	Strong	Genetic Variation	[73]
RIPK1	TTVJHX8	Definitive	Biomarker	[74]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC4A1	DTB0Q3P	moderate	Biomarker	[75]
ABCB5	DTKVEXO	Strong	Altered Expression	[76]

This Disease Is Related to 6 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
IPMK	DESA9EX	Limited	Biomarker	[77]
AKR1D1	DEVON3M	Strong	Genetic Variation	[78]
COLGALT2	DE8RIZD	Strong	Biomarker	[79]
CPA4	DEXKD7J	Strong	Altered Expression	[80]
CYP27A1	DEBS639	Strong	Genetic Variation	[81]
EPHX1	DELB4KP	Strong	Genetic Variation	[82]

This Disease Is Related to 124 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AFM	OTPOR8IO	Limited	Biomarker	[83]
AIRE	OTA7G1Y1	Limited	Biomarker	[84]
ARSH	OTG0X9UQ	Limited	Biomarker	[8]
BDH1	OT62RL5P	Limited	Altered Expression	[85]
CNOT3	OT4D5Z9L	Limited	Biomarker	[86]
CPT2	OTIN6G20	Limited	Biomarker	[5]
GCKR	OTSIWXGG	Limited	Genetic Variation	[87]
GOLGA6A	OTHU9MRX	Limited	Biomarker	[88]
GTF2A1L	OTDQHVAI	Limited	Biomarker	[83]
MPPE1	OTINBJVE	Limited	Biomarker	[89]
NCAN	OT8OO6ZE	Limited	Genetic Variation	[90]
P2RX2	OT0LF34A	Limited	Biomarker	[10]
P2RX6	OT1FNTXA	Limited	Biomarker	[10]
PIK3R5	OT4LNXJU	Limited	Biomarker	[91]
PTPRO	OTFLKWOY	Limited	Biomarker	[92]
RCBTB1	OTAYELI8	Limited	Biomarker	[88]
RIPK3	OTL1D484	Limited	Biomarker	[93]
RIPOR2	OTXB6LIR	Limited	Biomarker	[94]
SFPQ	OTLCIAPJ	Limited	Biomarker	[95]
STON1	OT2HPUAI	Limited	Biomarker	[83]
SYMPK	OTYAUDXV	Limited	Biomarker	[96]
SLAMF8	OTATVST8	Disputed	Biomarker	[97]
SLAMF9	OTH1OGZW	Disputed	Biomarker	[97]
CIDEA	OTDUTSOV	moderate	Altered Expression	[98]
CLEC7A	OTRTBH27	moderate	Biomarker	[99]
CLTC	OTBFASMA	moderate	Biomarker	[75]
ACOT7	OT7C68YV	Strong	Genetic Variation	[100]
ACTBL2	OTD6B81U	Strong	Genetic Variation	[100]
AHI1	OT8K2YWY	Strong	Biomarker	[101]
ALDH1L1	OT15HOJX	Strong	Altered Expression	[102]
AMELY	OTVG0EXE	Strong	Biomarker	[103]
APBA2	OTXD8ID1	Strong	Posttranslational Modification	[104]
ARC	OTN2QQPG	Strong	Altered Expression	[105]
ARFGEF1	OTPAU0L4	Strong	Altered Expression	[106]
ARID2	OTIRJXWM	Strong	Altered Expression	[106]
B4GALT1	OTBCXEK7	Strong	Altered Expression	[107]
BAMBI	OTCEJ8W5	Strong	Biomarker	[108]
CCL16	OTOOQI1F	Strong	Biomarker	[109]
CCL4L2	OTDBSXOU	Strong	Biomarker	[110]
CD5L	OTPY4WQR	Strong	Biomarker	[111]
CD81	OTQFXNAZ	Strong	Genetic Variation	[112]
CDSN	OTQW4HV6	Strong	Biomarker	[113]
COL15A1	OTTFKK18	Strong	Altered Expression	[114]
COMMD1	OT7WUD5R	Strong	Biomarker	[115]
DDX18	OTKB9C3S	Strong	Biomarker	[116]
DDX56	OTGURA53	Strong	Biomarker	[117]
DHX58	OT19BYB1	Strong	Biomarker	[118]
DLAT	OT9LBJVN	Strong	Biomarker	[119]
DMBT1	OTVNU9D9	Strong	Altered Expression	[120]
ECHS1	OTS0593S	Strong	Biomarker	[121]
EMB	OT67E3Q1	Strong	Biomarker	[122]
ESM1	OT331Y8V	Strong	Altered Expression	[123]
EXT1	OTRPALJK	Strong	Genetic Variation	[124]
FBL	OTRODIE5	Strong	Biomarker	[125]
FLT3LG	OTU0YGC4	Strong	Altered Expression	[126]
FUT8	OTJJCVG1	Strong	Altered Expression	[109]
GGTLC1	OTWJKUHQ	Strong	Biomarker	[127]
GNB3	OTA6HYBA	Strong	Genetic Variation	[128]
GNMT	OT0O2OQO	Strong	Biomarker	[129]
GOLM1	OTOZSV6O	Strong	Biomarker	[18]
GPT2	OTS5VF7N	Strong	Genetic Variation	[130]
GSPT1	OT18H1B0	Strong	Biomarker	[131]
HAS1	OTJIAG1W	Strong	Biomarker	[116]
HAS3	OTPM8IL8	Strong	Biomarker	[116]
HFE	OTDD93KB	Strong	Genetic Variation	[132]
IL17C	OTKXIVNQ	Strong	Biomarker	[133]
IL17RE	OTMFTNLS	Strong	Biomarker	[133]
IL18BP	OTW0LRYZ	Strong	Biomarker	[134]
IL27	OTIS3OF8	Strong	Biomarker	[44]
IL34	OTZ15VVK	Strong	Biomarker	[135]
IL9R	OTILCLXA	Strong	Altered Expression	[136]
KIF1B	OTI1XQTO	Strong	Genetic Variation	[137]
KLHL1	OTAX6SAD	Strong	Biomarker	[21]
KLRB1	OTQ2959Y	Strong	Biomarker	[138]
KRT18	OTVLQFIP	Strong	Altered Expression	[139]
LAMP3	OTN0XL3W	Strong	Biomarker	[140]
LGALS9	OT7MF91K	Strong	Altered Expression	[141]
LSAMP	OTYXVQX2	Strong	Biomarker	[140]
LTBP2	OTS88GSD	Strong	Biomarker	[142]
MBOAT7	OTHRCBLK	Strong	Biomarker	[143]
MLKL	OTDSLC81	Strong	Altered Expression	[144]
NAV2	OTGAOL01	Strong	Genetic Variation	[39]
NBAS	OTW9IBRI	Strong	Genetic Variation	[145]
NCKIPSD	OT24UORN	Strong	Biomarker	[101]
NELFE	OTL4E94L	Strong	Altered Expression	[146]
NSG1	OTRIMA50	Strong	Altered Expression	[147]
OXA1L	OTS0BFRD	Strong	Genetic Variation	[23]
PAEP	OTQA0NV4	Strong	Genetic Variation	[148]
PDLIM5	OTLQVV22	Strong	Biomarker	[149]
PGAM5	OT6Q5M0C	Strong	Altered Expression	[150]
PGLYRP2	OTF8319A	Strong	Biomarker	[151]
PIGR	OT6GLSUL	Strong	Biomarker	[152]
PLD4	OT5I74II	Strong	Genetic Variation	[153]
POTEM	OT7L2HGH	Strong	Genetic Variation	[100]
RDX	OTNSYUN6	Strong	Biomarker	[21]
RETN	OTW5Z1NH	Strong	Altered Expression	[154]
RHOF	OTPA3F8Q	Strong	Biomarker	[59]
RIT2	OTSNYG0D	Strong	Biomarker	[155]
RO60	OTLGM5A8	Strong	Biomarker	[156]
SAMSN1	OT7N88T1	Strong	Altered Expression	[157]
SARS1	OTFKXQ1O	Strong	Biomarker	[158]
SARS2	OTU4T99W	Strong	Biomarker	[158]
SERPINB4	OT88LHZ8	Strong	Altered Expression	[61]
SGMS1	OTZQE7PW	Strong	Biomarker	[159]
SIGLEC7	OTNDLURR	Strong	Biomarker	[160]
SMARCA5	OT5GR4Z2	Strong	Biomarker	[22]
SMN2	OT54RLO1	Strong	Biomarker	[62]
SON	OT9VWV18	Strong	Biomarker	[161]
SPAG9	OT45AHMB	Strong	Altered Expression	[162]
SPINT1	OT1CLR5L	Strong	Biomarker	[163]
SYCE1L	OTXU44F3	Strong	Biomarker	[21]
TCEAL1	OTAPG2L5	Strong	Altered Expression	[147]
TIMD4	OTGGC20G	Strong	Biomarker	[164]
TNFAIP8L2	OTII0RM0	Strong	Altered Expression	[165]
TRIM55	OTY5YQFX	Strong	Altered Expression	[166]
TRIM63	OTUSWA74	Strong	Altered Expression	[166]
CCL4	OT6B8P25	Definitive	Biomarker	[167]
IVNS1ABP	OTYHL4I7	Definitive	Biomarker	[168]
JAM2	OTHVJJRJ	Definitive	Biomarker	[169]
JAM3	OTX0F9QL	Definitive	Biomarker	[169]
MYOM2	OTD2UOXW	Definitive	Biomarker	[170]
RBM45	OTWTHD77	Definitive	Genetic Variation	[171]
SERPINA7	OTUYVTSU	Definitive	Biomarker	[172]
SETBP1	OTKGCOSR	Definitive	Biomarker	[173]

References

• [1] A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
• [2] Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.Biochem Biophys Res Commun. 2006 Mar 10;341(2):314-9. doi: 10.1016/j.bbrc.2005.12.192. Epub 2006 Jan 10.
• [3] Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death.Oxid Med Cell Longev. 2017;2017:1838679. doi: 10.1155/2017/1838679. Epub 2017 Jan 10.
• [4] Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease.Eur J Endocrinol. 2013 Oct 1;169(5):547-57. doi: 10.1530/EJE-13-0112. Print 2013 Nov.
• [5] L-carnitine ameliorates the liver inflammatory response by regulating carnitine palmitoyltransferase I-dependent PPAR signaling.Mol Med Rep. 2016 Feb;13(2):1320-8. doi: 10.3892/mmr.2015.4639. Epub 2015 Dec 4.
• [6] p65 down-regulates DEPTOR expression in response to LPS stimulation in hepatocytes.Gene. 2016 Sep 1;589(1):12-19. doi: 10.1016/j.gene.2016.05.014. Epub 2016 May 12.
• [7] DHA supplementation prevent the progression of NASH via GPR120 signaling.Eur J Pharmacol. 2018 Feb 5;820:31-38. doi: 10.1016/j.ejphar.2017.11.046. Epub 2017 Dec 6.
• [8] Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1 Transactivation in Steatohepatitis.Cell Metab. 2018 Feb 6;27(2):339-350.e3. doi: 10.1016/j.cmet.2018.01.007.
• [9] Type 3 cytokines in liver fibrosis and liver cancer.Cytokine. 2019 Dec;124:154497. doi: 10.1016/j.cyto.2018.07.028. Epub 2018 Aug 7.
• [10] Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation.Pharmacol Res. 2017 Mar;117:82-93. doi: 10.1016/j.phrs.2016.11.040. Epub 2016 Dec 8.
• [11] Sortilin Deficiency Reduces Ductular Reaction, Hepatocyte Apoptosis, and Liver Fibrosis in Cholestatic-Induced Liver Injury.Am J Pathol. 2017 Jan;187(1):122-133. doi: 10.1016/j.ajpath.2016.09.005. Epub 2016 Nov 11.
• [12] Host genetic background affects the course of infection and treatment response in patients with chronic hepatitis B.J Clin Virol. 2019 Nov;120:1-5. doi: 10.1016/j.jcv.2019.09.002. Epub 2019 Sep 3.
• [13] NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice.Hepatology. 2018 Feb;67(2):736-749. doi: 10.1002/hep.29523. Epub 2017 Dec 28.
• [14] Hepatoprotective role of Ricinus communis leaf extract against d-galactosamine induced acute hepatitis in albino rats.Biomed Pharmacother. 2017 Apr;88:658-666. doi: 10.1016/j.biopha.2017.01.073. Epub 2017 Jan 30.
• [15] Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma.BMC Cancer. 2010 Jul 6;10:356. doi: 10.1186/1471-2407-10-356.
• [16] Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-B/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.Hepatology. 2020 Apr;71(4):1262-1278. doi: 10.1002/hep.30917. Epub 2020 Jan 26.
• [17] PARP2 deficiency affects invariant-NKT-cell maturation and protects mice from concanavalin A-induced liver injury.Am J Physiol Gastrointest Liver Physiol. 2017 Nov 1;313(5):G399-G409. doi: 10.1152/ajpgi.00436.2016. Epub 2017 Jul 27.
• [18] Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B.Clin Chim Acta. 2019 Jun;493:92-97. doi: 10.1016/j.cca.2019.02.019. Epub 2019 Feb 20.
• [19] Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients.PLoS One. 2011;6(12):e28617. doi: 10.1371/journal.pone.0028617. Epub 2011 Dec 12.
• [20] Melatonin alleviates cadmium-induced liver injury by inhibiting the TXNIP-NLRP3 inflammasome.J Pineal Res. 2017 Apr;62(3). doi: 10.1111/jpi.12389. Epub 2017 Mar 10.
• [21] Changes in Radixin Expression and Interaction with Efflux Transporters in the Liver of Adjuvant-Induced Arthritic Rats.Inflammation. 2020 Feb;43(1):85-94. doi: 10.1007/s10753-019-01097-9.
• [22] Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma.Clin Chim Acta. 2019 May;492:37-44. doi: 10.1016/j.cca.2019.02.001. Epub 2019 Feb 2.
• [23] Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions.Drug Deliv. 2018 Nov;25(1):1067-1077. doi: 10.1080/10717544.2018.1464083.
• [24] Apolipoprotein A-II suppressed concanavalin A-induced hepatitis via the inhibition of CD4 T cell function.J Immunol. 2011 Mar 15;186(6):3410-20. doi: 10.4049/jimmunol.1002924. Epub 2011 Feb 7.
• [25] Early and severe liver disease associated with homozygosity for an exon 7 mutation, G691R, in Wilson's disease.Clin Genet. 2007 Sep;72(3):264-7. doi: 10.1111/j.1399-0004.2007.00853.x.
• [26] Expression and clinical significance of livin protein in hepatocellular carcinoma.Dis Markers. 2013;35(5):489-96. doi: 10.1155/2013/781740. Epub 2013 Oct 3.
• [27] Study on the relationship between level of CD58 expression in peripheral blood mononuclear cell and severity of HBV infection.Chin Med J (Engl). 2005 Dec 20;118(24):2072-6.
• [28] Circulating levels of CXCL11 and CXCL12 are biomarkers of cirrhosis in patients with chronic hepatitis C infection.Cytokine. 2019 May;117:72-78. doi: 10.1016/j.cyto.2019.02.006. Epub 2019 Feb 28.
• [29] Small Heterodimer Partner Deficiency Increases Inflammatory Liver Injury Through C-X-C motif chemokine ligand 2-Driven Neutrophil Recruitment in Mice.Toxicol Sci. 2018 May 1;163(1):254-264. doi: 10.1093/toxsci/kfy030.
• [30] Apoptosis of enterocytes and nitration of junctional complex proteins promote alcohol-induced gut leakiness and liver injury.J Hepatol. 2018 Jul;69(1):142-153. doi: 10.1016/j.jhep.2018.02.005. Epub 2018 Feb 16.
• [31] Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition.Chem Biol Interact. 2018 Feb 25;282:13-21. doi: 10.1016/j.cbi.2018.01.004. Epub 2018 Jan 8.
• [32] Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity.Life Sci. 2007 Sep 1;81(12):1009-15. doi: 10.1016/j.lfs.2007.08.013. Epub 2007 Aug 19.
• [33] Activities of Thrombin and Factor Xa Are Essential for Replication of Hepatitis E Virus and Are Possibly Implicated in ORF1 Polyprotein Processing.J Virol. 2018 Feb 26;92(6):e01853-17. doi: 10.1128/JVI.01853-17. Print 2018 Mar 15.
• [34] Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet.Am J Pathol. 2011 Nov;179(5):2278-89. doi: 10.1016/j.ajpath.2011.07.015. Epub 2011 Sep 9.
• [35] Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation.Am J Transplant. 2009 Sep;9(9):2197-202. doi: 10.1111/j.1600-6143.2009.02788.x.
• [36] FcRIIb on CD11c(+) cells modulates serum cholesterol and triglyceride levels and differentially affects atherosclerosis in male and female Ldlr(-/-) mice.Atherosclerosis. 2019 Jun;285:108-119. doi: 10.1016/j.atherosclerosis.2019.04.221. Epub 2019 Apr 13.
• [37] IL-33 protects murine viral fulminant hepatitis by targeting coagulation hallmark protein FGL2/fibroleukin expression.Mol Immunol. 2017 Jul;87:171-179. doi: 10.1016/j.molimm.2017.04.011. Epub 2017 May 8.
• [38] Chronic hepatitis B: The interplay between intrahepatic lymphocyte population and viral antigens in relation to liver damage.J Viral Hepat. 2019 Jun;26(6):727-737. doi: 10.1111/jvh.13078. Epub 2019 Mar 5.
• [39] Genome-wide association study of hepatitis in korean populations.Genomics Inform. 2014 Dec;12(4):203-7. doi: 10.5808/GI.2014.12.4.203. Epub 2014 Dec 31.
• [40] G Protein-Coupled Receptor 39 Agonist Improves Concanavalin A-Induced Hepatitis in Mice.Biol Pharm Bull. 2019 Aug 1;42(8):1415-1418. doi: 10.1248/bpb.b18-00982. Epub 2019 Jun 4.
• [41] Hepatic HKDC1 Expression Contributes to Liver Metabolism.Endocrinology. 2019 Feb 1;160(2):313-330. doi: 10.1210/en.2018-00887.
• [42] Heme oxygenase-1 attenuates low-dose of deoxynivalenol-induced liver inflammation potentially associating with microbiota.Toxicol Appl Pharmacol. 2019 Jul 1;374:20-31. doi: 10.1016/j.taap.2019.04.020. Epub 2019 Apr 26.
• [43] Interferon-lambda serum levels in hepatitis C.J Hepatol. 2011 May;54(5):859-65. doi: 10.1016/j.jhep.2010.08.020. Epub 2010 Oct 23.
• [44] Murine -Herpesvirus 68 Induces Severe Lung Inflammation in IL-27-Deficient Mice with Liver Dysfunction Preventable by Oral Neomycin.J Immunol. 2018 Apr 15;200(8):2703-2713. doi: 10.4049/jimmunol.1700412. Epub 2018 Mar 2.
• [45] CD8(+) T cell/IL-33/ILC2 axis exacerbates the liver injury in Con A-induced hepatitis in T cell-transferred Rag2-deficient mice.Inflamm Res. 2019 Jan;68(1):75-91. doi: 10.1007/s00011-018-1197-9. Epub 2018 Nov 14.
• [46] Rhabdomyolysis with concurrent atorvastatin and diltiazem.Ann Pharmacother. 2002 Oct;36(10):1546-9. doi: 10.1345/aph.1A481.
• [47] Genetic analysis of cytoprotective functions supported by graded expression of Keap1.Mol Cell Biol. 2010 Jun;30(12):3016-26. doi: 10.1128/MCB.01591-09. Epub 2010 Apr 19.
• [48] A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen-C on fibrosis progression in chronic C hepatitis with or without liver transplantation.Liver Int. 2016 Sep;36(9):1331-9. doi: 10.1111/liv.13057. Epub 2016 Jan 24.
• [49] Critical Contribution of NK Group 2 Member D Expressed on Invariant Natural Killer T Cells in Concanavalin A-Induced Liver Hepatitis in Mice.Front Immunol. 2018 May 17;9:1052. doi: 10.3389/fimmu.2018.01052. eCollection 2018.
• [50] Association of LTBR polymorphisms with chronic hepatitis B virus infection and hepatitis B virus-related hepatocellular carcinoma.Int Immunopharmacol. 2017 Aug;49:126-131. doi: 10.1016/j.intimp.2017.05.031. Epub 2017 May 30.
• [51] MyD88-dependent signaling in non-parenchymal cells promotes liver carcinogenesis.Carcinogenesis. 2020 Apr 22;41(2):171-181. doi: 10.1093/carcin/bgy173.
• [52] AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.Mol Genet Metab. 2017 Apr;120(4):299-305. doi: 10.1016/j.ymgme.2017.02.011. Epub 2017 Mar 2.
• [53] The chemical inhibitors of cellular death, PJ34 and Necrostatin-1, down-regulate IL-33 expression in liver. J Mol Med (Berl). 2015 Aug;93(8):867-78. doi: 10.1007/s00109-015-1270-6. Epub 2015 Mar 8.
• [54] PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production.Cell Res. 2008 Nov;18(11):1105-13. doi: 10.1038/cr.2008.294.
• [55] The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu.J Mol Med (Berl). 2019 Nov;97(11):1589-1600. doi: 10.1007/s00109-019-01836-3. Epub 2019 Oct 21.
• [56] Augmented liver inflammation in a microsomal prostaglandin E synthase 1 (mPGES-1)-deficient diet-induced mouse NASH model.Sci Rep. 2018 Oct 31;8(1):16127. doi: 10.1038/s41598-018-34633-y.
• [57] Spillover Events of Infection of Brown Hares (Lepus europaeus) with Rabbit Haemorrhagic Disease Type 2 Virus (RHDV2) Caused Sporadic Cases of an European Brown Hare Syndrome-Like Disease in Italy and Spain.Transbound Emerg Dis. 2017 Dec;64(6):1750-1761. doi: 10.1111/tbed.12562. Epub 2016 Sep 11.
• [58] Homologous 2',5'-phosphodiesterases from disparate RNA viruses antagonize antiviral innate immunity.Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13114-9. doi: 10.1073/pnas.1306917110. Epub 2013 Jul 22.
• [59] Prevalence of tuberculosis, HIV/AIDS, and hepatitis; in a prison of Balochistan: a cross-sectional survey.BMC Public Health. 2019 Dec 4;19(1):1631. doi: 10.1186/s12889-019-8011-7.
• [60] Diagnosis of alpha-1-antitrypsin deficiency in bleeding disorder-related neonatal death.Eur J Pediatr. 2011 Jan;170(1):103-6. doi: 10.1007/s00431-010-1280-x. Epub 2010 Sep 2.
• [61] Ferritin light chain and squamous cell carcinoma antigen 1 are coreceptors for cellular attachment and entry of hepatitis B virus.Int J Nanomedicine. 2012;7:827-34. doi: 10.2147/IJN.S27803. Epub 2012 Feb 16.
• [62] Di(2-ethylhexyl) phthalate promotes hepatic fibrosis by regulation of oxidative stress and inflammation responses in rats.Environ Toxicol Pharmacol. 2019 May;68:109-119. doi: 10.1016/j.etap.2019.03.008. Epub 2019 Mar 8.
• [63] Liver metabolism in adult male mice offspring: consequences of a maternal, paternal or both maternal and paternal high-fructose diet.J Dev Orig Health Dis. 2018 Aug;9(4):450-459. doi: 10.1017/S2040174418000235. Epub 2018 Apr 17.
• [64] Lack of the matricellular protein SPARC (secreted protein, acidic and rich in cysteine) attenuates liver fibrogenesis in mice.PLoS One. 2013;8(2):e54962. doi: 10.1371/journal.pone.0054962. Epub 2013 Feb 11.
• [65] Association analysis of hepatitis virus B infection with haplotypes of the TBX21 gene promoter region in the Chinese population.Clin Chem Lab Med. 2007;45(3):333-8. doi: 10.1515/CCLM.2007.062.
• [66] The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO). Immunol Lett. 2020 Jan;217:25-30.
• [67] Medullary thymic epithelial cell depletion leads to autoimmune hepatitis.J Clin Invest. 2013 Aug;123(8):3510-24. doi: 10.1172/JCI65414. Epub 2013 Jul 15.
• [68] Murine Coronavirus Infection Activates the Aryl Hydrocarbon Receptor in an Indoleamine 2,3-Dioxygenase-Independent Manner, Contributing to Cytokine Modulation and Proviral TCDD-Inducible-PARP Expression.J Virol. 2020 Jan 17;94(3):e01743-19. doi: 10.1128/JVI.01743-19. Print 2020 Jan 17.
• [69] Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2016 Nov 10;17(11):1878. doi: 10.3390/ijms17111878.
• [70] Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.Clin Cancer Res. 2018 Mar 1;24(5):1138-1151. doi: 10.1158/1078-0432.CCR-17-1847. Epub 2018 Jan 4.
• [71] Functional Genomics Identifies Hepatitis-Induced STAT3-TYRO3-STAT3 Signaling as a Potential Therapeutic Target of Hepatoma.Clin Cancer Res. 2020 Mar 1;26(5):1185-1197. doi: 10.1158/1078-0432.CCR-18-3531. Epub 2019 Dec 12.
• [72] "Gilbert's-like" syndrome as part of a spectrum of persistent unconjugated hyperbilirubinemia in post-chronic hepatitis patients.Sci Rep. 2018 Jan 31;8(1):2008. doi: 10.1038/s41598-018-19847-4.
• [73] Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFN/RBV therapy.J Appl Genet. 2015 Aug;56(3):403-9. doi: 10.1007/s13353-014-0267-0. Epub 2015 Jan 15.
• [74] RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis.J Hepatol. 2017 Jun;66(6):1205-1213. doi: 10.1016/j.jhep.2017.01.005. Epub 2017 Jan 11.
• [75] Upregulation of CXCR3 expression on CD8+ T cells due to the pervasive influence of chronic hepatitis B and C virus infection.Hum Immunol. 2013 Aug;74(8):899-906. doi: 10.1016/j.humimm.2013.04.017. Epub 2013 Apr 30.
• [76] Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance.Gastroenterology. 2011 Jan;140(1):344-55. doi: 10.1053/j.gastro.2010.07.049. Epub 2010 Aug 2.
• [77] IPMK Mediates Activation of ULK Signaling and Transcriptional Regulation of Autophagy Linked to Liver Inflammation and Regeneration.Cell Rep. 2019 Mar 5;26(10):2692-2703.e7. doi: 10.1016/j.celrep.2019.02.013.
• [78] Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. Gut. 2003 Oct;52(10):1494-9. doi: 10.1136/gut.52.10.1494.
• [79] Glt25d2 Knockout Directly Increases CD25+CD69- but Decreases CD25-CD69+ Subset Proliferation and is Involved in Concanavalin-Induced Hepatitis.Cell Physiol Biochem. 2018;50(3):1186-1200. doi: 10.1159/000494546. Epub 2018 Oct 24.
• [80] Association between expression of Carboxypeptidase 4 and stem cell markers and their clinical significance in liver cancer development.J Cancer. 2017 Jan 1;8(1):111-116. doi: 10.7150/jca.17060. eCollection 2017.
• [81] Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis.J Inherit Metab Dis. 2002 Oct;25(6):501-13. doi: 10.1023/a:1021211520034.
• [82] Haplotypes of microsomal epoxide hydrolase and x-ray cross-complementing group 1 genes in Indian hepatocellular carcinoma patients.DNA Cell Biol. 2009 Nov;28(11):573-7. doi: 10.1089/dna.2009.0921.
• [83] The Role of Monocytes and Macrophages in Acute and Acute-on-Chronic Liver Failure.Front Immunol. 2018 Dec 14;9:2948. doi: 10.3389/fimmu.2018.02948. eCollection 2018.
• [84] Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1.Hepatology. 2001 May;33(5):1047-52. doi: 10.1053/jhep.2001.24031.
• [85] Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans.Liver Int. 2015 Jul;35(7):1853-61. doi: 10.1111/liv.12769. Epub 2015 Jan 20.
• [86] Insufficient liver maturation affects murine early postnatal hair cycle.Biochem Biophys Res Commun. 2020 Jan 1;521(1):172-177. doi: 10.1016/j.bbrc.2019.10.099. Epub 2019 Oct 18.
• [87] Genetics of nonalcoholic fatty liver disease.Metabolism. 2016 Aug;65(8):1026-37. doi: 10.1016/j.metabol.2015.08.018. Epub 2015 Sep 1.
• [88] Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD.Front Endocrinol (Lausanne). 2018 Nov 6;9:649. doi: 10.3389/fendo.2018.00649. eCollection 2018.
• [89] Characterization of Antigen-Presenting Cell Subsets in Human Liver-Draining Lymph Nodes.Front Immunol. 2019 Mar 14;10:441. doi: 10.3389/fimmu.2019.00441. eCollection 2019.
• [90] Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity.Hum Hered. 2013;75(1):34-43. doi: 10.1159/000346195. Epub 2013 Apr 10.
• [91] Transcriptome analysis revealed ameliorative effect of probiotic Lactobacillus johnsonii BS15 against subclinical necrotic enteritis induced hepatic inflammation in broilers.Microb Pathog. 2019 Jul;132:201-207. doi: 10.1016/j.micpath.2019.05.011. Epub 2019 May 8.
• [92] Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-B activation.J Immunol. 2014 Nov 15;193(10):5161-70. doi: 10.4049/jimmunol.1303354. Epub 2014 Oct 22.
• [93] Activated TNF-/RIPK3 signaling is involved in prolonged high fat diet-stimulated hepatic inflammation and lipid accumulation: inhibition by dietary fisetin intervention.Food Funct. 2019 Mar 20;10(3):1302-1316. doi: 10.1039/c8fo01615a.
• [94] Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.OMICS. 2017 Mar;21(3):123-131. doi: 10.1089/omi.2017.0006. Epub 2017 Feb 16.
• [95] Binding of the polypyrimidine tract-binding protein-associated splicing factor (PSF) to the hepatitis delta virus RNA.Virology. 2006 Dec 5-20;356(1-2):35-44. doi: 10.1016/j.virol.2006.06.040. Epub 2006 Aug 30.
• [96] Telmisartan and/or chlorogenic acid attenuates fructose-induced non-alcoholic fatty liver disease in rats: Implications of cross-talk between angiotensin, the sphingosine kinase/sphingoine-1-phosphate pathway, and TLR4 receptors.Biochem Pharmacol. 2019 Jun;164:252-262. doi: 10.1016/j.bcp.2019.04.018. Epub 2019 Apr 18.
• [97] Combined deficiency of SLAMF8 and SLAMF9 prevents endotoxin-induced liver inflammation by downregulating TLR4 expression on macrophages.Cell Mol Immunol. 2020 Feb;17(2):153-162. doi: 10.1038/s41423-018-0191-z. Epub 2018 Dec 14.
• [98] The Differential Expression of Cide Family Members is Associated with Nafld Progression from Steatosis to Steatohepatitis.Sci Rep. 2019 May 16;9(1):7501. doi: 10.1038/s41598-019-43928-7.
• [99] Intestinal fungi contribute to development of alcoholic liver disease.J Clin Invest. 2017 Jun 30;127(7):2829-2841. doi: 10.1172/JCI90562. Epub 2017 May 22.
• [100] Enhancement of hepatitis virus immunoassay outcome predictions in imbalanced routine pathology data by data balancing and feature selection before the application of support vector machines.BMC Med Inform Decis Mak. 2017 Aug 14;17(1):121. doi: 10.1186/s12911-017-0522-5.
• [101] Transfusion-transmitted virus co-infection in other types of hepatitis and its genotypes.Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):90-3.
• [102] ALDH1L1 variant rs2276724 and mRNA expression predict post-operative clinical outcomes and are associated with TP53 expression in HBV-related hepatocellular carcinoma.Oncol Rep. 2017 Sep;38(3):1451-1463. doi: 10.3892/or.2017.5822. Epub 2017 Jul 14.
• [103] AFP computational secreted network construction and analysis between human hepatocellular carcinoma (HCC) and no-tumor hepatitis/cirrhotic liver tissues.Tumour Biol. 2010 Oct;31(5):417-25. doi: 10.1007/s13277-010-0050-8. Epub 2010 Jun 8.
• [104] Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas.Mod Pathol. 2009 Mar;22(3):442-9. doi: 10.1038/modpathol.2008.203. Epub 2009 Jan 9.
• [105] Is liver-targeted FOXp3 staining beneficial after living-donor liver transplantation?.Transpl Infect Dis. 2012 Apr;14(2):156-62. doi: 10.1111/j.1399-3062.2011.00690.x. Epub 2011 Oct 31.
• [106] P200 family protein IFI204 negatively regulates type I interferon responses by targeting IRF7 in nucleus.PLoS Pathog. 2019 Oct 11;15(10):e1008079. doi: 10.1371/journal.ppat.1008079. eCollection 2019 Oct.
• [107] Identification of beta-1,4-galactosyltransferase I as a target gene of HBx-induced cell cycle progression of hepatoma cell.J Hepatol. 2008 Dec;49(6):1029-37. doi: 10.1016/j.jhep.2008.09.003. Epub 2008 Sep 26.
• [108] Adiponectin induces the transforming growth factor decoy receptor BAMBI in human hepatocytes.FEBS Lett. 2011 May 6;585(9):1338-44. doi: 10.1016/j.febslet.2011.04.003. Epub 2011 Apr 7.
• [109] The alpha1-6-fucosyltransferase gene and its biological significance.Biochim Biophys Acta. 1999 Dec 6;1473(1):9-20. doi: 10.1016/s0304-4165(99)00166-x.
• [110] Immunomodulative effects of mesenchymal stem cells derived from human embryonic stem cells in vivo and in vitro.J Zhejiang Univ Sci B. 2011 Jan;12(1):18-27. doi: 10.1631/jzus.B1000074.
• [111] CD5L is a pleiotropic player in liver fibrosis controlling damage, fibrosis and immune cell content.EBioMedicine. 2019 May;43:513-524. doi: 10.1016/j.ebiom.2019.04.052. Epub 2019 May 8.
• [112] CD81 nucleotide mutation in hepatocellular carcinoma and lack of CD81 polymorphism in patients at stages of hepatitis C virus infection.J Med Virol. 2001 Jan;63(1):22-8.
• [113] Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.Vaccine. 2008 Feb 6;26(6):797-808. doi: 10.1016/j.vaccine.2007.11.092. Epub 2007 Dec 26.
• [114] Human collagen XV is a prominent histopathological component of sinusoidal capillarization in hepatocellular carcinogenesis.Int J Clin Oncol. 2016 Apr;21(2):302-309. doi: 10.1007/s10147-015-0888-2. Epub 2015 Aug 21.
• [115] Copper-induced hepatitis: the COMMD1 deficient dog as a translational animal model for human chronic hepatitis.Vet Q. 2011 Mar;31(1):49-60. doi: 10.1080/01652176.2011.563146.
• [116] The Hepatitis Aggressiveness Score (HAS): a novel classification system for post-liver transplantation recurrent hepatitis C.Am J Surg Pathol. 2013 Jan;37(1):104-13. doi: 10.1097/PAS.0b013e31826a92ac.
• [117] DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control.Oncogene. 2006 Mar 30;25(14):1991-2003. doi: 10.1038/sj.onc.1209239.
• [118] New Techniques to Study Intracellular Receptors in Living Cells: Insights Into RIG-I-Like Receptor Signaling.Adv Exp Med Biol. 2019;1111:219-240. doi: 10.1007/5584_2018_297.
• [119] Recent developments in autoimmune liver diseases.J Gastroenterol Hepatol. 1997 Oct;12(9-10):S256-71. doi: 10.1111/j.1440-1746.1997.tb00509.x.
• [120] Expression of deleted in malignant brain tumours 1 (DMBT1) relates to the proliferation and malignant transformation of hepatic progenitor cells in hepatitis B virus-related liver diseases.Histopathology. 2012 Jan;60(2):249-60. doi: 10.1111/j.1365-2559.2011.04082.x.
• [121] ECHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochondrial pathway in HepG2 cells.Cancer Lett. 2013 Mar 1;330(1):67-73. doi: 10.1016/j.canlet.2012.11.030. Epub 2012 Nov 23.
• [122] Genetic alterations of the putative envelope proteins encoding region of the hepatitis C virus in the progression to relapsed phase from acute hepatitis: humoral immune response to hypervariable region 1.Int J Cancer. 1994 Jun 1;57(5):664-70. doi: 10.1002/ijc.2910570509.
• [123] ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma.Amino Acids. 2011 Mar;40(3):1003-13. doi: 10.1007/s00726-010-0729-6. Epub 2010 Sep 7.
• [124] TT virus in Hungary: sequence heterogeneity and mixed infections.FEMS Immunol Med Microbiol. 2003 Mar 20;35(2):153-7. doi: 10.1016/S0928-8244(03)00005-1.
• [125] Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.J Gastroenterol Hepatol. 2019 Jan;34(1):207-214. doi: 10.1111/jgh.14448. Epub 2018 Sep 18.
• [126] Ratios of T-helper 2 Cells to T-helper 1 Cells and Cytokine Levels in Patients with Hepatitis B.Chin Med J (Engl). 2017 Aug 5;130(15):1810-1815. doi: 10.4103/0366-6999.211541.
• [127] Hepatic Lesions Associated With McCune Albright Syndrome.J Pediatr Gastroenterol Nutr. 2019 Apr;68(4):e54-e57. doi: 10.1097/MPG.0000000000002266.
• [128] GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection.J Hepatol. 2005 Sep;43(3):388-93. doi: 10.1016/j.jhep.2005.03.020.
• [129] Deficiency of glycine N-methyltransferase results in deterioration of cellular defense to stress in mouse liver.Proteomics Clin Appl. 2010 Apr;4(4):394-406. doi: 10.1002/prca.200900074. Epub 2010 Jan 25.
• [130] A promising non-invasive index for predicting liver inflammation in chronic hepatitis B patients with alanine aminotransferase ? upper limit of normal.Exp Ther Med. 2018 Dec;16(6):4393-4400. doi: 10.3892/etm.2018.6751. Epub 2018 Sep 18.
• [131] Liver glutathione S-transferase polymorphism in Japanese and its pharmacogenetic importance. Hum Genet. 1987 Apr;75(4):322-5. doi: 10.1007/BF00284101.
• [132] Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma.Blood Cells Mol Dis. 2005 Jul-Aug;35(1):27-32. doi: 10.1016/j.bcmd.2005.03.007.
• [133] IL-17C/IL-17RE Augments T Cell Function in Autoimmune Hepatitis.J Immunol. 2017 Jan 15;198(2):669-680. doi: 10.4049/jimmunol.1600977. Epub 2016 Dec 12.
• [134] Inherited IL-18BP deficiency in human fulminant viral hepatitis. J Exp Med. 2019 Aug 5;216(8):1777-1790. doi: 10.1084/jem.20190669. Epub 2019 Jun 18.
• [135] Interleukin-34 drives macrophage polarization to the M2 phenotype in autoimmune hepatitis.Pathol Res Pract. 2019 Aug;215(8):152493. doi: 10.1016/j.prp.2019.152493. Epub 2019 Jun 10.
• [136] TGF-/Smad signaling pathway positively up-regulates the differentiation of Interleukin-9-producing CD4(+) T cells in human Echinococcus granulosus infection.J Infect. 2018 Apr;76(4):406-416. doi: 10.1016/j.jinf.2018.01.005. Epub 2018 Feb 2.
• [137] Role of single nucleotide polymorphisms of KIF1B gene in HBV-associated viral hepatitis.PLoS One. 2012;7(9):e45128. doi: 10.1371/journal.pone.0045128. Epub 2012 Sep 18.
• [138] Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells.J Immunol. 2004 Aug 1;173(3):2159-66. doi: 10.4049/jimmunol.173.3.2159.
• [139] Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease.Mediators Inflamm. 2017;2017:3480234. doi: 10.1155/2017/3480234. Epub 2017 Jul 30.
• [140] Detection of HCV genotypes 1b and 2a by a reverse transcription loop-mediated isothermal amplification assay.J Med Virol. 2017 Jun;89(6):1048-1054. doi: 10.1002/jmv.24747. Epub 2017 Mar 14.
• [141] Molecular cloning, characterization and expression analysis of Tim-3 and Galectin-9 in the woodchuck model.Mol Immunol. 2017 Mar;83:127-136. doi: 10.1016/j.molimm.2017.01.018. Epub 2017 Jan 30.
• [142] Expression and clinical significance of latent-transforming growth factor beta-binding protein 2 in primary hepatocellular carcinoma.Medicine (Baltimore). 2019 Sep;98(39):e17216. doi: 10.1097/MD.0000000000017216.
• [143] Lysophosphatidylinositol-acyltransferase-1 is involved in cytosolic Ca(2+) oscillations in macrophages.Genes Cells. 2019 May;24(5):366-376. doi: 10.1111/gtc.12681. Epub 2019 Apr 16.
• [144] The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.J Clin Invest. 2016 Nov 1;126(11):4346-4360. doi: 10.1172/JCI87545. Epub 2016 Oct 17.
• [145] Neuroblastoma amplified sequence gene mutation: A rare cause of recurrent liver failure in children.Saudi J Gastroenterol. 2017 May-Jun;23(3):206-208. doi: 10.4103/1319-3767.207714.
• [146] Overexpression of the RD RNA binding protein in hepatitis C virus-related hepatocellular carcinoma.Oncol Rep. 2012 Aug;28(2):728-34. doi: 10.3892/or.2012.1821. Epub 2012 May 18.
• [147] P21 expression and its relation to disease activity and hepatocyte proliferation in chronic hepatitis B virus infection.Turk J Gastroenterol. 2005 Mar;16(1):12-6.
• [148] The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.Medicine (Baltimore). 2017 Jul;96(29):e7554. doi: 10.1097/MD.0000000000007554.
• [149] Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection.Hepatol Int. 2016 Jan;10(1):133-8. doi: 10.1007/s12072-015-9657-6. Epub 2015 Oct 1.
• [150] PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury.Gut. 2017 Apr;66(4):716-723. doi: 10.1136/gutjnl-2015-311247. Epub 2016 Aug 26.
• [151] Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease.Am J Physiol Gastrointest Liver Physiol. 2013 Sep 1;305(5):G364-74. doi: 10.1152/ajpgi.00077.2013. Epub 2013 Jun 27.
• [152] The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma.J Natl Cancer Inst. 2011 Nov 16;103(22):1696-712. doi: 10.1093/jnci/djr360. Epub 2011 Oct 24.
• [153] PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing.Nat Immunol. 2018 Sep;19(9):942-953. doi: 10.1038/s41590-018-0179-y. Epub 2018 Aug 13.
• [154] The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis.BMC Gastroenterol. 2014 Feb 23;14:39. doi: 10.1186/1471-230X-14-39.
• [155] Clinical significance of hepatitis C virus (HCV) infection in liver transplant recipients. Role of serology and HCV RNA detection.Dig Dis Sci. 1994 May;39(5):965-9. doi: 10.1007/BF02087545.
• [156] Immune responses to Ro60 and its peptides in mice. I. The nature of the immunogen and endogenous autoantigen determine the specificities of the induced autoantibodies.J Exp Med. 1999 Feb 1;189(3):531-40. doi: 10.1084/jem.189.3.531.
• [157] Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1453-60. doi: 10.1245/s10434-015-4524-1. Epub 2015 Mar 25.
• [158] Severe acute respiratory syndrome coronavirus protein 6 accelerates murine hepatitis virus infections by more than one mechanism.J Virol. 2008 Jul;82(14):7212-22. doi: 10.1128/JVI.02406-07. Epub 2008 Apr 30.
• [159] Sphingomyelin synthase 1 enhances BCR signaling to promote lupus-like autoimmune response.EBioMedicine. 2019 Jul;45:578-587. doi: 10.1016/j.ebiom.2019.06.038. Epub 2019 Jun 28.
• [160] Serum soluble sialic acid-binding immunoglobulin-like lectin-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease.Hepatol Res. 2020 Apr;50(4):466-477. doi: 10.1111/hepr.13464. Epub 2019 Dec 26.
• [161] The role of SON in splicing, development, and disease.Wiley Interdiscip Rev RNA. 2014 Sep-Oct;5(5):637-46. doi: 10.1002/wrna.1235. Epub 2014 Apr 30.
• [162] The expression of DAMP proteins HSP70 and cancer-testis antigen SPAG9 in peripheral blood of patients with HCC and lung cancer.Cell Stress Chaperones. 2017 Mar;22(2):237-244. doi: 10.1007/s12192-016-0758-5. Epub 2016 Dec 27.
• [163] Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma.Biochem Biophys Res Commun. 2001 Nov 23;289(1):205-11. doi: 10.1006/bbrc.2001.5916.
• [164] Tim-4 Inhibits NLRP3 Inflammasome via the LKB1/AMPK Pathway in Macrophages.J Immunol. 2019 Aug 15;203(4):990-1000. doi: 10.4049/jimmunol.1900117. Epub 2019 Jul 1.
• [165] Tumor necrosis factor--induced protein 8-like 2 (TIPE2) is associated with immune phases of patients with chronic hepatitis B.Oncotarget. 2017 May 9;8(19):30781-30792. doi: 10.18632/oncotarget.15683.
• [166] The E3 ubiquitin ligase MuRF2 attenuates LPS-induced macrophage activation by inhibiting production of inflammatory cytokines and migration.FEBS Open Bio. 2018 Jan 8;8(2):234-243. doi: 10.1002/2211-5463.12367. eCollection 2018 Feb.
• [167] The A3 adenosine receptor agonist, namodenoson, ameliorates nonalcoholic steatohepatitis in mice.Int J Mol Med. 2019 Dec;44(6):2256-2264. doi: 10.3892/ijmm.2019.4364. Epub 2019 Oct 3.
• [168] Detection of antibody to hepatitis C E2/NS1 protein in patients with type C hepatitis.Biochem Biophys Res Commun. 1992 Nov 30;189(1):565-71. doi: 10.1016/0006-291x(92)91595-h.
• [169] Junctional adhesion molecules JAM-B and JAM-C promote autoimmune-mediated liver fibrosis in mice.J Autoimmun. 2018 Jul;91:83-96. doi: 10.1016/j.jaut.2018.05.001. Epub 2018 May 9.
• [170] The cytoplasmic tail of mouse hepatitis virus M protein is essential but not sufficient for its retention in the Golgi complex.J Biol Chem. 1994 Nov 11;269(45):28263-9.
• [171] The association between the genetic polymorphism of HLA-DQA1, DQB1, and DRB1 and serum alanine aminotransferase levels in chronic hepatitis C in the Chinese population.J Gastroenterol Hepatol. 2008 Sep;23(9):1394-402. doi: 10.1111/j.1440-1746.2007.05215.x. Epub 2007 Nov 19.
• [172] Normal cellular uptake of thyroxine from serum of patients with familial dysalbuminemic hyperthyroxinemia or elevated thyroxine-binding globulin.J Clin Endocrinol Metab. 1988 Dec;67(6):1166-70. doi: 10.1210/jcem-67-6-1166.
• [173] In vitro activation of woodchuck lymphocytes measured by radiopurine incorporation and interleukin-2 production: implications for modeling immunity and therapy in hepatitis B virus infection.Hepatology. 1995 Sep;22(3):687-99.